Groupe Hospitalier Bichat-Claude Bernard
Paris, 75018, France
NCT Number: NCT00328653
The primary objective of this study is:
* To assess the efficacy of Nova22007, a cyclosporine A (CsA), 0.05% and 0.1% versus vehicle in patients with vernal keratoconjunctivitis (VKC) after a 4-week treatment period.
The secondary objectives of this study are:
* To compare the safety and ocular tolerance of Nova22007 0.05% and 0.1%; * To assess the long term safety and ocular tolerance of Nova22007 0.05% and 0.1%; and * To assess the decrease in frequency of concomitant artificial tears use.
Looking for future studies?
Notify Me4 year and older
All sexes
Interventional
Phase 2 / Phase 3
Paris, 75018, France
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: Week 4
The primary criteria of the trial was the overall rating of subjective symptoms in ocular symptoms of VKC as compared to Baseline and assessed at Week 4 (Month 1) based on a five-point scale based on BenEzra trial (BenEzra 1986):
Time frame: Week 4
Overall rating of objective signs was to be assessed under the slit lamp by the Investigator and recorded on a five-point scale based on BenEzra trial (BenEzra 1986):
Time frame: Up to Month1
Time frame: Up to Month1
Are the tested eye drops (other than concomitant tear substitute ) comfortable?
Santen SAS
Industry
Phase II/III, Multicenter, Double-Masked, Randomized, Parallel Group, Dose Ranging, Controlled Trial of Efficacy and Tolerance of Nova22007 (Cyclosporine A [CSA] 0.05% & 0.1% Ophthalmic Cationic Emulsion) Versus Vehicle in Patients With VKC
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05038241
Conjunctival Diseases, Conjunctivitis
Milan, Italy
View Trial DetailsNCT04389034
Allergic Asthma, Allergic Conjunctivitis
Cologne, Germany
View Trial DetailsNCT03101618
Allergic Conjunctivitis, Allergic Rhinitis
Incheon, South Korea
View Trial DetailsNCT04641130
Allergic Conjunctivitis, Conjunctival Diseases
Strasbourg, Grand Est, France
View Trial Details